Aeon Biopharma price target lowered to $5 from $6 at H.C. Wainwright

H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Aeon Biopharma to $5 from $6 and keeps a Buy rating on the shares. The analyst believes the outcome of the biosimilar meeting should clarify the development path for ABP-450 and should attract investor interest to provide the program’s needed funding.